Two Sigma Advisers LP Boosts Stake in LivaNova PLC (NASDAQ:LIVN)

Two Sigma Advisers LP increased its position in LivaNova PLC (NASDAQ:LIVN) by 148.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 214,545 shares of the company’s stock after buying an additional 128,200 shares during the period. Two Sigma Advisers LP’s holdings in LivaNova were worth $9,936,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in LivaNova by 12.7% during the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock valued at $108,823,000 after purchasing an additional 265,291 shares during the period. Capital Research Global Investors raised its position in LivaNova by 19.1% during the fourth quarter. Capital Research Global Investors now owns 1,612,818 shares of the company’s stock valued at $74,690,000 after purchasing an additional 258,730 shares during the period. Dimensional Fund Advisors LP raised its position in LivaNova by 8.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company’s stock valued at $60,710,000 after purchasing an additional 107,693 shares during the period. Redmile Group LLC raised its position in LivaNova by 19.3% during the fourth quarter. Redmile Group LLC now owns 1,043,539 shares of the company’s stock valued at $48,326,000 after purchasing an additional 168,500 shares during the period. Finally, Nuveen Asset Management LLC raised its position in LivaNova by 0.6% during the fourth quarter. Nuveen Asset Management LLC now owns 823,412 shares of the company’s stock valued at $38,132,000 after purchasing an additional 5,080 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Price Performance

Shares of LivaNova stock opened at $43.18 on Friday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $61.94. The business has a 50-day moving average price of $38.74 and a 200 day moving average price of $44.71. The firm has a market cap of $2.35 billion, a PE ratio of 102.81 and a beta of 0.84.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LIVN shares. Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research report on Tuesday, May 13th. Robert W. Baird increased their price target on LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Wolfe Research upgraded LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a report on Tuesday. Stifel Nicolaus reduced their price target on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group reduced their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, LivaNova presently has an average rating of “Buy” and a consensus target price of $59.29.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.